---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058618"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:31:57.826589+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end

## Summary
- Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.
- Net loss $18.7M ($0.73/share) vs $9.2M loss ($0.37) in Q1 2023; operating expenses $26.8M.
- Full-year 2024 commercial revenue expected at lower end of $78.5-84.5M range, implying ~57% growth.
- Launched PermeaDerm biosynthetic wound matrix in US on March 23, 2024.
- RECELL GO FDA decision by May 30, 2024; cashflow breakeven targeted no later than Q3 2025.

## SEC filing metadata
- accession: 0000950170-24-058618
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/0000950170-24-058618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/rcel-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058618
- JSON: https://secwatch.observer/filing/0000950170-24-058618.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058618.txt

## Key facts
- Earnings Releases
  AVITA Medical, Inc. updated its first quarter ended March 31, 2024 guidance (lowered).
  - Period: first quarter ended March 31, 2024
  - Guidance: lowered
  - Result: reported results
  source text: On May 13, 2024, AVITA Medical, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000095017024058618/0000950170-24-058618-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.